Frozen section could spare rectal cancer patients from major surgery
NCT ID NCT07337811
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial is testing whether a quick lab test during surgery can help some people with low rectal cancer avoid a major operation. After radiation therapy, patients with a good response undergo a small local excision. If the frozen section shows no deep cancer, they skip the larger surgery and enter a watch-and-wait program. If cancer is deeper, they get immediate complete removal. The goal is to see if this selective approach keeps cancer under control while reducing complications and preserving quality of life.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Selective total mesorectal excision based on intra-operative frozen section
- What this could lead to
- If successful, this approach could allow many patients with low rectal cancer to avoid major surgery and a permanent colostomy, preserving bowel function and quality of life.
- What could go wrong
- This is a small, early-phase trial with only 27 participants, so results may not apply broadly. There is a risk that the frozen-section analysis may miss cancer cells, leading to undertreatment or recurrence.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 27 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Aug 2025
- Expected to finish
-
Jul 2028
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 75 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Pathologically confirmed rectal adenocarcinoma. 2. Neoadjuvant therapy based on radiotherapy; post-radiotherapy evaluation ≥8 weeks later shows near clinical complete response (near-cCR) or partial response (PR) with residual tumor \<2 cm. 3. Tumor distance from the anal verge ≤5 cm. 4. Age 18-75 years. 5. No synchronous multiple primary cancers. 6. No contraindications to pre-operative radiotherapy or chemotherapy. 7. Adequate organ function (cardiac, hepatic, renal, hematologic). 8. Patient or legally authorized representative able to understand the study protocol, willing to participate, and provide written informed consent. Exclusion Criteria: 1. Age \<18 or \>75 years. 2. Concurrent or previous malignancy within the past 5 years (except adequately treated basal-cell or squamous-cell skin carcinoma or carcinoma in situ of the cervix). 3. Emergency surgery required for bowel obstruction, perforation, or bleeding. 4. Prior colorectal surgery that may compromise intestinal reconstruction. 5. Need for en-bloc multivisceral resection. 6. ASA physical status IV or V. 7. Pregnant or lactating women. 8. a) Women of child-bearing potential with a positive serum pregnancy test at baseline or who have not undergone pregnancy testing; post-menopausal women must have been amenorrheic for ≥12 months. 9. b) Men or women of reproductive potential unwilling to use effective contraception throughout the study period. 10. Severe psychiatric illness precluding informed consent or compliance. 11. Severe COPD, interstitial lung disease, or ischemic heart disease precluding safe surgery. 12. Continuous systemic corticosteroid therapy within 1 month before enrolment. 13. Contraindications to laparoscopic surgery. 14. Patient or legally authorized representative unable to understand the study conditions and objectives.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Rectal adenocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Dept. of Colorectal Surgery, Sun Yat-sen University Cancer Center. Yuexiu District, Dongfeng East Road 651
RECRUITINGGuangzhou, Guanggong, 510060, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New injectable drug tested against Hard-to-Treat solid tumors
- Could a nasal tube replace a temporary ileostomy after rectal cancer surgery?
- Blood test aims to catch Cancer's return earlier
- Blood test guides immunotherapy for hidden cancer cells
- Can Pre-Surgery radiation stop rectal cancer from returning?
- Can a counseling program restore intimacy after rectal cancer?